PUBLISHER: IMARC | PRODUCT CODE: 1986742
PUBLISHER: IMARC | PRODUCT CODE: 1986742
The global aortic valve replacement market size reached USD 12.3 Billion in 2025. Looking forward, IMARC Group expects the market to reach USD 27.1 Billion by 2034, exhibiting a growth rate (CAGR) of 8.87% during 2026-2034. The increasing prevalence of aortic diseases, rising implementation of health insurance policies, and the growing adoption of MIS procedures represent some of the key factors driving the market.
Aortic valve replacement is a surgical procedure performed to replace a diseased or damaged aortic valve in the heart. It is usually operated through the traditional open-heart surgery, which involves incising the chest or using minimally invasive (MI) methods that require smaller incisions in the chest or a catheter incorporated in the leg. It treats diseases that affect the valves and controls blood flow through the heart. It aids in restoring normal blood flow, reducing symptoms, prolonging life, and preserving the function of the heart muscle. It is generally recommended for patients with severe aortic valve disease, including aortic stenosis or aortic regurgitation, that has symptoms like chest pain, shortness of breath, and fatigue.
The surging prevalence of aortic diseases among the masses and the increasing aging population that is more prone to developing these medical disorders represent one of the major factors driving the demand for aortic valve replacement around the world. Moreover, the rising implementation of health insurance policies that offer financial assistance for aortic valve replacement and reduce medical expenses is favoring the growth of the market. In addition, the growing awareness about aortic diseases, their symptoms, diagnosis, and the easy availability of the treatment options like aortic valve replacement is influencing the market positively. Apart from this, there is an increase in the adoption of transcatheter aortic valve replacement (TAVR), minimally invasive surgical (MIS) procedure that helps replace the aortic valve without open-heart surgery and is generally preferred by patients who are at major risk for traditional open-heart surgery. This, coupled with the rising preferences for MIS procedures on account of fewer operative complications, shorter hospitalization, less pain, reduced postoperative care, quicker recovery, and lower risk of infection, is propelling the growth of the market. Furthermore, the integration of artificial intelligence (AI) and machine learning (ML) in imaging techniques of aortic valve replacement to identify patients who are at higher risk for complications and optimize the procedure and postoperative care is contributing to the market growth. Besides this, governing agencies of numerous countries are undertaking measures to offer quality healthcare facilities that are accessible to all. This, along with significant improvements in the diagnostic technologies, is strengthening the growth of the market.
The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America (the United States and Canada) was the largest market for aortic valve replacement. Some of the factors driving the North America aortic valve replacement market included extensive research and development (R&D) activities, well established healthcare facilities, integration of advanced technologies, etc.
The report has also provided a comprehensive analysis of the competitive landscape in the global aortic valve replacement market. Competitive analysis such as market structure, market share by key players, player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided. Some of the companies covered include Abbott Laboratories, Anteris Technologies Ltd., Boston Scientific Corporation, Coroneo Inc., CryoLife Inc., Edward Lifesciences Corporation, JenaValve Technology Inc., LifeNet Health Inc., LivaNova PLC, Medtronic plc, Thubrikar Aortic Valve Inc., etc. Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.